HomeArchive by category 'News' (Page 5)

News - News and Articles about commonly prescribed drugs

New anti-HER2 drug reveals promising anti-tumor exercise in gullet, abdomen and bowel cancers

Posted in News on 15th November 2018

An antibody that binds concurrently to 2 distinct areas of the HER2 receptor to dam the expansion of most cancers cells has proven promising indicators of anti-tumor exercise in a variety of cancers together with these of the gullet (esophagus), abdomen and bowel.

Outcomes from the part I scientific trial of the drug, referred to as ZW25, had been introduced earlier this 12 months , however up to date outcomes, specializing in sufferers with esophageal, abdomen, bowel and a number of other different cancers pushed by HER2, have been introduced at present (Wednesday) on the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Most cancers Therapeutics in Dublin, Eire.

HER2, a member of the human epidermal progress issue receptor household, is greatest recognized for the position it performs in breast most cancers. Trastuzumab (Herceptin) is an efficient remedy for HER2‑constructive breast cancers. Abdomen cancers which are pushed by HER2 additionally reply nicely to trastuzumab, but when most cancers returns in these sufferers, there aren’t any additional accepted HER2‑focused brokers. Sadly, for sufferers with different HER2‑pushed cancers, there are at the moment no accepted HER2‑focused brokers.

Dr Murali Beeram, a medical oncologist and scientific investigator on the START Middle for Most cancers Care, San Antonio, USA, informed the Symposium that as of 16 October a complete of 24 sufferers, who had obtained a number of earlier therapies (a mean of 4) however whose cancers had returned, have been given between one and ten cycles of ZW25 since becoming a member of the part I trial, which began in September 2016 (both 10 mg/kg weekly or 20 mg/kg each different week). All had HER2 constructive cancers, together with cancers of the oesophagus and abdomen (gastroesophageal) (10 sufferers), bowel (5), gall bladder (three), bile duct (1), cervix (1), endometrial (1) fallopian tube (1), pores and skin (adnexal) (1), and parotid gland (1), and eight of those sufferers stay within the trial.

The most recent ends in 17 sufferers with responses accessible for analysis present that 13 skilled shrinkage of their tumor. The median time the sufferers survived with out their illness progressing was 6.21 months. Unintended effects have been principally gentle or average with the commonest being diarrhea or a response to the infusion of the drug.

Dr Beeram mentioned: “As a clinician, I’m excited by the one agent anti-tumor exercise and tolerability we’re seeing with ZW25, notably in these patents with superior HER2‑expressing cancers which have progressed after a number of prior therapies, together with HER2‑focused brokers.The truth is, trastuzumab is the one HER2‑focused remedy accepted for gastric most cancers and there aren’t any accepted HER2-targeted therapies for different kinds of most cancers which are pushed by the HER2 receptor. ZW25 has been nicely tolerated to this point, which ought to enable it for use together with different brokers for probably even higher responses.”

ZW25 is an antibody that may concurrently bind two distinct areas of the HER2 receptor, a protein that promotes the expansion of most cancers cells. Dr Beeram defined: “This distinctive design ends in a number of mechanisms of motion, together with twin HER2 sign blockade, elevated binding, and elimination of HER2 protein from the most cancers cell floor; it additionally stimulates the immune system to assault the most cancers cells. This has led to encouraging anti-tumor exercise in sufferers whose tumors have stopped responding to accepted therapies, and who’re in determined want of recent medicines that present anti-tumor exercise with out extreme poisonous uncomfortable side effects. The spectacular exercise of ZW25, mixed with its tolerability, is notable and needs to be investigated additional.”

Along with the cancers already talked about, a variety of others are also pushed by the HER2 protein; they embody cancers of the womb, ovaries, lung and bladder. Zymeworks, the corporate that developed ZW25, has expanded the research and a part II/III research for sufferers with oesophageal, abdomen, and different cancers is deliberate for subsequent 12 months. As well as, research are deliberate to research ZW25 together with different anti-cancer medicine in sufferers with cancers which have an overabundance of HER2 receptors and copies of the HER2 gene, and likewise in these with fewer HER2 receptors and gene copies.

Co-chair of the EORTC-NCI-AACR Symposium, Professor Antoni Ribas from the College of California Los Angeles, who was not concerned within the analysis, commented: “Though these are early outcomes on a small variety of sufferers, they recommend that this new HER2 focused antibody can affect difficult-to-treat cancers which have both failed to answer earlier therapies or have recurred. We look ahead to additional outcomes from this research, in addition to the additional research which are deliberate.”

Supply:

https://www.ecco-org.eu/

FDA Points Security Alert Concerning Intrathecal Supply of Ache Meds

Posted in News on 15th November 2018

Если Вы считаете, что включение ip-адреса нужного Вам интернет-ресурса в “Единый реестр…” или “Реестр доменных имен…” произошло по ошибке, или оно нарушает Ваши законные права, пожалуйста, обращайтесь непосредственно к уполномоченному органу по координатам на интернет-сайте реестра.

Перейти на сайт
Универсального сервиса проверки ограничения доступа к сайтам или страницам сайтов сети “Интернет”

Can a Doctor Be Assessed Punitive Damages for Altering or Destroying Medical Information?

Posted in News on 14th November 2018
The jury found that Dr E had departed from the accepted standard of medical care

The jury found that Dr E had departed from the accepted standard of medical care

This month we look at the interesting question of whether a plaintiff in a malpractice lawsuit against a clinician may recover punitive damages when the clinician destroys or changes medical records in an attempt to avoid malpractice liability.

The case involved a 6-year old girl, Miss C, whose mother took her to a new pediatrician, Dr P, in mid-October. The pediatrician recommended that Miss C see a pediatric endocrinologist because the child’s blood sugar level was high. The girl’s mother asked Dr P for a referral and the pediatrician recommended Dr E.

Dr E, the endocrinologist, worked from a private office in the basement of her home. Her sister served as her office manager, and her two nephews helped with billing and appointment scheduling. The office was low-tech, and Dr E had a habit of using what she called “scribble notes” during exams and then typing the notes into the medical record at some later point in time.

Continue Reading Below

Dr E saw the patient a total of 3 times – in late October, in mid-November, and in mid-December. Meanwhile, the patient’s pediatrician also saw her again in late November, and then early January.

The endocrinologist concluded that the child was obese and developing type 2 diabetes. At the conclusion of the mid-December office visit, the child’s mother was given an appointment card for an appointment two months later, in mid-February.

Tragically, the child never made that appointment. In late January, Miss C came home from school complaining of lethargy and that she wasn’t feeling well. She brought home a note from the school nurse describing her symptoms. That evening the child had a stomachache and vomited. The next day, the mother tried to have the child seen by the pediatrician, but she was not available, so the mother took Miss C to the hospital. The child remained in the hospital until her death, 3 days later. 

The final autopsy report revealed the cause of death to be attributable to “bilateral cerebellar tonsillar herniation secondary to cerebral edema following diabetic ketoacidosis.”

Cheap and efficient drug doesn’t cut back main hostile cardiovascular occasion charges

Posted in News on 13th November 2018

On the subject of decreasing irritation to lower the chance of coronary heart illness and stroke, outcomes from the much-anticipated Cardiovascular Irritation Discount Trial (CIRT) point out that focusing on the appropriate inflammatory pathways in at-risk sufferers is essential. Final 12 months, the Canakinumab Anti-inflammatory Thrombosis Outcomes Research (CANTOS) confirmed that the interleukin-1? inhibitor canakinumab each focused a particular inflammatory pathway and consequently lowered charges of coronary heart assault and cardiovascular demise. Against this, the findings from CIRT confirmed that low-dose methotrexate neither inhibited that very same inflammatory pathway nor lowered main hostile cardiovascular occasion charges. These outcomes had been introduced by Paul Ridker, MD, director of the Middle for Cardiovascular Illness Prevention at Brigham and Ladies’s Hospital, throughout the American Coronary heart Affiliation Scientific Periods 2018, and revealed concurrently in The New England Journal of Medication.

“The contrasting outcomes between these two modern medical trials exhibit the significance of contemplating the mechanistic range of inflammatory pathways and of approaches to their inhibition,” mentioned Ridker. “Understanding these variations might be essential for future research focusing on irritation in atherosclerosis.”

Previous to CIRT, observational research had prompt that low-dose methotrexate, a cheap and efficient drug extensively used to deal with rheumatoid arthritis and different inflammatory illnesses, may cut back charges of cardiovascular occasions. The federally-funded CIRT was designed to carefully check whether or not low-dose methotrexate may successfully cut back threat of main hostile cardiovascular occasions – that’s, coronary heart assaults, stroke and cardiovascular demise. In parallel, Ridker and colleagues additionally designed and performed CANTOS, sponsored by Novartis, to check the identical outcomes for canakinumab, a drug that particularly targets interleukin-1β. Interleukin-1 is a pro-inflammatory cytokine that, if over-produced, ends in elevated irritation all through the physique in addition to elevated ranges of interleukin-6 and excessive sensitivity C-reactive protein (hsCRP), two essential biomarkers of irritation.

CIRT and CANTOS had been each randomized, double-blind, placebo-controlled trials, and each enrolled steady however high-risk atherosclerosis sufferers. CANTOS, nonetheless, was designed to incorporate solely sufferers with persistently elevated hsCRP ranges. CIRT didn’t make use of this criterion, and the typical hsCRP degree for the inhabitants was nicely throughout the regular vary. CIRT enrolled four,786 North American sufferers with prior coronary heart assault or multi-vessel coronary illness who moreover had both sort 2 diabetes or a metabolic syndrome. The trial stopped after a median follow-up of two.three years.

In contrast to canakinumab as utilized in CANTOS, low-dose methotrexate as utilized in CIRT didn’t cut back the inflammatory pathway main from interleukin-1 to interleukin-6 and on to hsCRP. Concordantly, and in distinction to canakinumab, low-dose methotrexate didn’t decrease cardiovascular occasion charges in comparison with placebo. The crew experiences that 201 sufferers taking methotrexate suffered a significant cardiovascular occasion in comparison with 207 sufferers taking the placebo. But, methotrexate was related to elevations of liver enzymes, reductions in leucocytes and hematocrit, and the next incidence of non-basal cell pores and skin cancers.

“The outcomes from CIRT and CANTOS, when thought-about collectively, inform us one thing critically necessary: Not all irritation is identical, and never all medication that concentrate on irritation are the identical,” mentioned Ridker. “Whereas it’s disappointing that a cheap drug like methotrexate didn’t have the consequences we beforehand noticed in CANTOS, the outcomes from CIRT shed essential mild on the underlying biology that connects irritation with heart problems. The divergent trial outcomes present a transparent roadmap to information our efforts going ahead.”

Regardless of its vast medical use, the organic mechanisms underlying the anti-inflammatory results of methotrexate in rheumatoid arthritis and different inflammatory situations stays poorly understood. Medicine comparable to colchicine and oral NLRP3 inhibitors which will intersect with the interleukin 1 to interleukin-6 to CRP pathway are at present underneath investigation or in improvement.

“CANTOS and CIRT present the cardiovascular group proof-of-principle that particular focusing on of the interleukin-1 to interleukin-6 pathway of innate immunity is essential for stopping atherothrombotic occasions. The analysis purpose now and the medical want of our sufferers is to seek out cheap and extensively relevant brokers that may safely goal this pathway,” Ridker mentioned.

Supply:

https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=3191

HHS: Up to date Bodily Exercise Tips for Individuals Launched

Posted in News on 13th November 2018

November 12, 2018

Preschool-aged children (ages 3–5 years) should be physically active throughout the day

Preschool-aged children (ages 3–5 years) should be physically active throughout the day

The US Department of Health and Human Services (HHS) has released the second edition of the Physical Activity Guidelines for Americans at the American Heart Association’s Scientific Sessions meeting. This document complements the Dietary Guidelines for Americans, which was released by the HHS and the US Department of Agriculture (USDA). The new edition was developed by the 2018 Physical Activity Guidelines Advisory Committee who conducted systematic reviews of available scientific literature.

This guidance, updated for the first time since 2008, provides evidence-based recommendations for children (ages 3-17) and adults. Specifically, it includes new guidelines for children aged 3–5 years and updated recommendations for children and adolescents aged 6–17 years, adults, older adults, women during pregnancy and the postpartum period, and adults with chronic health conditions or disabilities. The second edition outlines the types and amounts of activity recommended for these various populations. For example, while the previous guidelines had suggested that for adults, bouts of at least 10 minutes of physical activity were necessary, the new guidelines state that some physical activity is better than none, even if it is less than 10 minutes.

For preschool-aged children, the Committee recommends:

  • Preschool-aged children (ages 3–5 years) should be physically active throughout the day to enhance growth and development 
  • Adult caregivers of preschool-aged children should encourage active play that includes a variety of activity types

“Probably the most important message from the 2018 guidelines is that the greatest health benefits accrue by moving from no, to even small amounts of, physical activity, especially if that activity is of moderate (eg, brisk walking) or vigorous (eg, jogging and running) intensity,” stated Paul D Thompson MD and Thijs MH Eijsvogels, PhD, in a recent JAMA Editorial. “The point for clinicians is that physical activity should be strongly considered as primary or adjunctive therapy for many common clinical conditions such as mild depression, anxiety, and sleep difficulties.”

The executive summary of the key guidelines can be found here. 

Related Articles

For more information visit Health.gov.

Scroll down to see the next article
Page 5 of 108:« 1 2 3 4 5 6 7 8 9 10 » Last »